{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T17:02:31Z","timestamp":1784998951840,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10147-026-03071-6","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T14:41:28Z","timestamp":1783176088000},"page":"1607-1618","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between response to gemcitabine-based neoadjuvant therapy and efficacy of gemcitabine plus nab-paclitaxel for recurrent pancreatic ductal adenocarcinoma"],"prefix":"10.1007","volume":"31","author":[{"given":"Takumi","family":"Kinomoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7517-8960","authenticated-orcid":false,"given":"Kenji","family":"Ikezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihito","family":"Gotoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugo","family":"Kai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Masumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Urabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Mukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasuku","family":"Nakabori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Shigekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Akita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Ohkawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"key":"3071_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74:12\u201349. https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"key":"3071_CR2","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S0140-6736(25)00261-2","volume":"405","author":"TF Stoop","year":"2025","unstructured":"Stoop TF, Javed AA, Oba A et al (2025) Pancreatic cancer. Lancet 405:1182\u20131202. https:\/\/doi.org\/10.1016\/S0140-6736(25)00261-2","journal-title":"Lancet"},{"key":"3071_CR3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","volume":"8","author":"P Ghaneh","year":"2023","unstructured":"Ghaneh P, Palmer D, Cicconi S et al (2023) Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 8:157\u2013168. https:\/\/doi.org\/10.1016\/S2468-1253(22)00348-X","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3071_CR4","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ejca.2021.10.023","volume":"160","author":"JL van Dam","year":"2022","unstructured":"van Dam JL, Janssen QP, Besselink MG et al (2022) Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomised controlled trials. Eur J Cancer 160:140\u2013149. https:\/\/doi.org\/10.1016\/j.ejca.2021.10.023","journal-title":"Eur J Cancer"},{"key":"3071_CR5","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.pan.2024.09.009","volume":"24","author":"H Ueda","year":"2024","unstructured":"Ueda H, Takahashi H, Sakaniwa R et al (2024) Preoperative treatment response prediction for pancreatic cancer by multiple microRNAs in plasma exosomes: optimization using machine learning and network analysis. Pancreatology 24:1097\u20131106. https:\/\/doi.org\/10.1016\/j.pan.2024.09.009","journal-title":"Pancreatology"},{"key":"3071_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/sla.0000000000006730","volume":"283","author":"M Unno","year":"2025","unstructured":"Unno M, Motoi F, Matsuyama Y et al (2025) Neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer: results of the randomized phase II\/III Prep-02\/JSAP05 trial. Ann Surg 283:57\u201364. https:\/\/doi.org\/10.1097\/sla.0000000000006730","journal-title":"Ann Surg"},{"key":"3071_CR7","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1097\/SLA.0000000000005430","volume":"275","author":"J Yamaguchi","year":"2022","unstructured":"Yamaguchi J, Yokoyama Y, Fujii T et al (2022) Results of a phase II study on the use of neoadjuvant chemotherapy (FOLFIRINOX or GEM\/nab-PTX) for borderline-resectable pancreatic cancer (NUPAT-01). Ann Surg 275:1043\u20131049. https:\/\/doi.org\/10.1097\/SLA.0000000000005430","journal-title":"Ann Surg"},{"key":"3071_CR8","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1245\/s10434-018-6512-8","volume":"25","author":"M Dhir","year":"2018","unstructured":"Dhir M, Zenati MS, Hamad A et al (2018) FOLFIRINOX versus gemcitabine\/nab-paclitaxel for neoadjuvant treatment of resectable and borderline resectable pancreatic head adenocarcinoma. Ann Surg Oncol 25:1896\u20131903. https:\/\/doi.org\/10.1245\/s10434-018-6512-8","journal-title":"Ann Surg Oncol"},{"key":"3071_CR9","doi-asserted-by":"publisher","unstructured":"Labori KJ, Bratlie SO, Andersson B et al (2024) Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 9:205\u2013217. https:\/\/doi.org\/10.1016\/S2468-1253(23)00405-3","DOI":"10.1016\/S2468-1253(23)00405-3"},{"key":"3071_CR10","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41571-025-01019-9","volume":"22","author":"SB Dreyer","year":"2025","unstructured":"Dreyer SB, Beer P, Hingorani SR et al (2025) Improving outcomes of patients with pancreatic cancer. Nat Rev Clin Oncol 22:439\u2013456. https:\/\/doi.org\/10.1038\/s41571-025-01019-9","journal-title":"Nat Rev Clin Oncol"},{"key":"3071_CR11","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1200\/JCO.21.02233","volume":"40","author":"E Versteijne","year":"2022","unstructured":"Versteijne E, van Dam JL, Suker M et al (2022) Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch Randomized PREOPANC trial. J Clin Oncol 40:1220\u20131230. https:\/\/doi.org\/10.1200\/JCO.21.02233","journal-title":"J Clin Oncol"},{"key":"3071_CR12","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1177\/0003134821998671","volume":"88","author":"K Okano","year":"2022","unstructured":"Okano K, Suto H, Oshima M et al (2022) Role of short-term neoadjuvant chemoradiotherapy for potentially resectable pancreatic cancer. Am Surg 88:1298\u20131303. https:\/\/doi.org\/10.1177\/0003134821998671","journal-title":"Am Surg"},{"key":"3071_CR13","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.ijrobp.2025.02.037","volume":"122","author":"HY Wu","year":"2025","unstructured":"Wu HY, Tsou HH, Lu LS et al (2025) Role of neoadjuvant chemoradiation therapy for resectable and borderline resectable pancreatic adenocarcinoma-a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys 122:1257\u20131271. https:\/\/doi.org\/10.1016\/j.ijrobp.2025.02.037","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3071_CR14","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1097\/SLA.0b013e31829b3ce4","volume":"258","author":"H Takahashi","year":"2013","unstructured":"Takahashi H, Ohigashi H, Gotoh K et al (2013) Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Ann Surg 258:1040\u20131050. https:\/\/doi.org\/10.1097\/SLA.0b013e31829b3ce4","journal-title":"Ann Surg"},{"key":"3071_CR15","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1097\/SLA.0000000000001547","volume":"264","author":"H Takahashi","year":"2016","unstructured":"Takahashi H, Akita H, Tomokuni A et al (2016) Preoperative gemcitabine-based chemoradiation therapy for borderline resectable pancreatic cancer: impact of venous and arterial involvement status on surgical outcome and pattern of recurrence. Ann Surg 264:1091\u20131097. https:\/\/doi.org\/10.1097\/SLA.0000000000001547","journal-title":"Ann Surg"},{"key":"3071_CR16","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","volume":"388","author":"K Uesaka","year":"2016","unstructured":"Uesaka K, Boku N, Fukutomi A et al (2016) Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388:248\u2013257. https:\/\/doi.org\/10.1016\/S0140-6736(16)30583-9","journal-title":"Lancet"},{"key":"3071_CR17","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1097\/SLA.0000000000002234","volume":"267","author":"VP Groot","year":"2018","unstructured":"Groot VP, Rezaee N, Wu W et al (2018) Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg 267:936\u2013945. https:\/\/doi.org\/10.1097\/SLA.0000000000002234","journal-title":"Ann Surg"},{"key":"3071_CR18","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1002\/bjs.11295","volume":"106","author":"M Tanaka","year":"2019","unstructured":"Tanaka M, Mihaljevic AL, Probst P et al (2019) Meta-analysis of recurrence pattern after resection for pancreatic cancer. Br J Surg 106:1590\u20131601. https:\/\/doi.org\/10.1002\/bjs.11295","journal-title":"Br J Surg"},{"key":"3071_CR19","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1001\/jamasurg.2019.3337","volume":"154","author":"RP Jones","year":"2019","unstructured":"Jones RP, Psarelli EE, Jackson R et al (2019) Patterns of recurrence after resection of pancreatic ductal adenocarcinoma: a secondary analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy trial. JAMA Surg 154:1038\u20131048. https:\/\/doi.org\/10.1001\/jamasurg.2019.3337","journal-title":"JAMA Surg"},{"key":"3071_CR20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1159\/000236022","volume":"77","author":"K Hashimoto","year":"2009","unstructured":"Hashimoto K, Ueno H, Ikeda M et al (2009) Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment? Oncology 77:217\u2013223. https:\/\/doi.org\/10.1159\/000236022","journal-title":"Oncology"},{"key":"3071_CR21","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1186\/s12885-019-5630-4","volume":"19","author":"OB Gbolahan","year":"2019","unstructured":"Gbolahan OB, Tong Y, Sehdev A et al (2019) Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study. BMC Cancer 19:468. https:\/\/doi.org\/10.1186\/s12885-019-5630-4","journal-title":"BMC Cancer"},{"key":"3071_CR22","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1200\/JCO.24.00936","volume":"43","author":"A Ohba","year":"2025","unstructured":"Ohba A, Ozaka M, Mizusawa J et al (2025) Modified fluorouracil, leucovorin, irinotecan, and oxaliplatin or S-1, irinotecan, and oxaliplatin versus nab-paclitaxel + gemcitabine in metastatic or recurrent pancreatic cancer (GENERATE, JCOG1611): a randomized, open-label, phase II\/III trial. J Clin Oncol 43:3345\u20133354. https:\/\/doi.org\/10.1200\/JCO.24.00936","journal-title":"J Clin Oncol"},{"key":"3071_CR23","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DDV Hoff","year":"2013","unstructured":"Hoff DDV, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691\u20131703. https:\/\/doi.org\/10.1056\/NEJMoa1304369","journal-title":"N Engl J Med"},{"key":"3071_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1276037","volume":"13","author":"H Li","year":"2023","unstructured":"Li H, Guo Y, Sun X et al (2023) Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study. Front Oncol 13:1276037. https:\/\/doi.org\/10.3389\/fonc.2023.1276037","journal-title":"Front Oncol"},{"key":"3071_CR25","doi-asserted-by":"publisher","unstructured":"Okusaka T (2022) Treatment for postoperative recurrence of pancreatic cancer: a narrative review. Chin Clin Oncol 11:19. https:\/\/doi.org\/10.21037\/cco-21-87","DOI":"10.21037\/cco-21-87"},{"key":"3071_CR26","doi-asserted-by":"publisher","unstructured":"Taguchi H, Otsuka T, Shimokawa M et al (2021) Gemcitabine plus nanoparticle albumin-bound paclitaxel versus FOLFIRINOX for recurrent pancreatic cancer after resection. Anticancer Res 41:3573\u20133582. https:\/\/doi.org\/10.21873\/anticanres.15145","DOI":"10.21873\/anticanres.15145"},{"key":"3071_CR27","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1097\/MPA.0000000000001140","volume":"47","author":"H Takahashi","year":"2018","unstructured":"Takahashi H, Akita H, Ioka T et al (2018) Phase I trial evaluating the safety of preoperative gemcitabine\/nab-paclitaxel with concurrent radiation therapy for borderline resectable pancreatic cancer. Pancreas 47:1135\u20131141. https:\/\/doi.org\/10.1097\/MPA.0000000000001140","journal-title":"Pancreas"},{"key":"3071_CR28","doi-asserted-by":"publisher","first-page":"4498","DOI":"10.1245\/s10434-019-07735-8","volume":"26","author":"H Eguchi","year":"2019","unstructured":"Eguchi H, Takeda Y, Takahashi H et al (2019) A prospective, open-label, multicenter phase 2 trial of neoadjuvant therapy using full-dose gemcitabine and S-1 concurrent with radiation for resectable pancreatic ductal adenocarcinoma. Ann Surg Oncol 26:4498\u20134505. https:\/\/doi.org\/10.1245\/s10434-019-07735-8","journal-title":"Ann Surg Oncol"},{"key":"3071_CR29","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"3071_CR30","doi-asserted-by":"publisher","unstructured":"Ishida M, Fujii T, Kishiwada M et al (2024) Japanese classification of pancreatic carcinoma by the Japan Pancreas Society: eighth edition. J Hepatobiliary Pancreat Sci 31:755\u2013768. https:\/\/doi.org\/10.1002\/jhbp.12056","DOI":"10.1002\/jhbp.12056"},{"key":"3071_CR31","volume-title":"TNM classification of malignant tumours","author":"JD Brierley","year":"2017","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C (2017) TNM classification of malignant tumours. Wiley-Blackwell"},{"key":"3071_CR32","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"3071_CR33","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1097\/sla.0000000000002734","volume":"269","author":"VP Groot","year":"2019","unstructured":"Groot VP, Gemenetzis G, Blair AB et al (2019) Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma. Ann Surg 269:1154\u20131162. https:\/\/doi.org\/10.1097\/sla.0000000000002734","journal-title":"Ann Surg"},{"key":"3071_CR34","doi-asserted-by":"publisher","unstructured":"van Oosten AF, Daamen LA, Groot VP et al (2023) Predicting post-recurrence survival for patients with pancreatic cancer recurrence after primary resection: a bi-institutional validated risk classification. Eur J Surg Oncol 49:106910. https:\/\/doi.org\/10.1016\/j.ejso.2023.04.009","DOI":"10.1016\/j.ejso.2023.04.009"},{"key":"3071_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100485","volume":"7","author":"I Ghanem","year":"2022","unstructured":"Ghanem I, Lora D, Herrad\u00f3n N et al (2022) Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials. ESMO Open 7:100485. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100485","journal-title":"ESMO Open"},{"key":"3071_CR36","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10147-023-02317-x","volume":"28","author":"T Okusaka","year":"2023","unstructured":"Okusaka T, Nakamura M, Yoshida M et al (2023) Clinical practice guidelines for pancreatic cancer 2022 from the Japan Pancreas Society: a synopsis. Int J Clin Oncol 28:493\u2013511. https:\/\/doi.org\/10.1007\/s10147-023-02317-x","journal-title":"Int J Clin Oncol"},{"key":"3071_CR37","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1186\/s12885-022-10130-4","volume":"22","author":"L Miotke","year":"2022","unstructured":"Miotke L, Nevala-Plagemann C, Ying J et al (2022) Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: a real world study. BMC Cancer 22:1054. https:\/\/doi.org\/10.1186\/s12885-022-10130-4","journal-title":"BMC Cancer"},{"key":"3071_CR38","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/1078-0432.CCR-18-3781","volume":"25","author":"HM McGee","year":"2019","unstructured":"McGee HM, Jiang D, Soto-Pantoja DR et al (2019) Targeting the tumor microenvironment in radiation oncology: proceedings from the 2018 ASTRO-AACR research workshop. Clin Cancer Res 25:2969\u20132974. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3781","journal-title":"Clin Cancer Res"},{"key":"3071_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030768","volume":"15","author":"S Benkhaled","year":"2023","unstructured":"Benkhaled S, Peters C, Jullian N et al (2023) Combination, modulation and interplay of modern radiotherapy with the tumor microenvironment and targeted therapies in pancreatic cancer: which candidates to boost radiotherapy? Cancers (Basel) 15:768. https:\/\/doi.org\/10.3390\/cancers15030768","journal-title":"Cancers (Basel)"},{"key":"3071_CR40","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nrc3958","volume":"15","author":"HE Barker","year":"2015","unstructured":"Barker HE, Paget JT, Khan AA et al (2015) The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer 15:409\u2013425. https:\/\/doi.org\/10.1038\/nrc3958","journal-title":"Nat Rev Cancer"},{"key":"3071_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1266537","volume":"11","author":"D Zhao","year":"2023","unstructured":"Zhao D, Mo Y, Neganova ME et al (2023) Dual effects of radiotherapy on tumor microenvironment and its contribution towards the development of resistance to immunotherapy in gastrointestinal and thoracic cancers. Front Cell Dev Biol 11:1266537. https:\/\/doi.org\/10.3389\/fcell.2023.1266537","journal-title":"Front Cell Dev Biol"},{"key":"3071_CR42","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1200\/JCO-24-02210","volume":"43","author":"M Ducreux","year":"2025","unstructured":"Ducreux M, Desgrippes R, Rinaldi Y et al (2025) PRODIGE 29-UCGI 26 (NEOPAN): a phase III randomized trial comparing chemotherapy with FOLFIRINOX or gemcitabine in locally advanced pancreatic carcinoma. J Clin Oncol 43:2255\u20132264. https:\/\/doi.org\/10.1200\/JCO-24-02210","journal-title":"J Clin Oncol"},{"key":"3071_CR43","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M et al (2019) Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 381:317\u2013327. https:\/\/doi.org\/10.1056\/NEJMoa1903387","journal-title":"N Engl J Med"},{"key":"3071_CR44","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/3809095","volume":"2021","author":"C He","year":"2021","unstructured":"He C, Cai Z, Zhang Y et al (2021) Comparative recurrence analysis of pancreatic adenocarcinoma after resection. J Oncol 2021:3809095. https:\/\/doi.org\/10.1155\/2021\/3809095","journal-title":"J Oncol"},{"key":"3071_CR45","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.pan.2020.05.020","volume":"20","author":"H Takahashi","year":"2020","unstructured":"Takahashi H, Yamada D, Asukai K et al (2020) Clinical implications of the serum CA19-9 level in \u201cbiological borderline resectability\u201d and \u201cbiological downstaging\u201d in the setting of preoperative chemoradiation therapy for pancreatic cancer. Pancreatology 20:919\u2013928. https:\/\/doi.org\/10.1016\/j.pan.2020.05.020","journal-title":"Pancreatology"},{"key":"3071_CR46","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/SLA.0b013e3181cc90a3","volume":"251","author":"H Takahashi","year":"2010","unstructured":"Takahashi H, Ohigashi H, Ishikawa O et al (2010) Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival. Ann Surg 251:461\u2013469. https:\/\/doi.org\/10.1097\/SLA.0b013e3181cc90a3","journal-title":"Ann Surg"},{"key":"3071_CR47","doi-asserted-by":"publisher","unstructured":"Homma Y, Miyake K, Kikuchi Y et al (2025) Prognostic significance of post-neoadjuvant chemotherapy carbohydrate antigen 19\u20139 levels in patients with resectable pancreatic cancer treated with S-1 and gemcitabine: a retrospective cohort study. World J Oncol 16:269\u2013275. https:\/\/doi.org\/10.14740\/wjon2563","DOI":"10.14740\/wjon2563"},{"key":"3071_CR48","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.pan.2025.06.016","volume":"25","author":"S Miyahara","year":"2025","unstructured":"Miyahara S, Takahashi H, Tomimaru Y et al (2025) Prognostic impact of post-neoadjuvant CA19-9 values in pancreatic cancer: more pronounced following neoadjuvant chemotherapy compared to neoadjuvant chemoradiotherapy. Pancreatology 25:728\u2013735. https:\/\/doi.org\/10.1016\/j.pan.2025.06.016","journal-title":"Pancreatology"},{"key":"3071_CR49","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1002\/ags3.70047","volume":"9","author":"S Miyahara","year":"2025","unstructured":"Miyahara S, Takahashi H, Tomimaru Y et al (2025) Discrepancy between radiographic and pathological response assessment in neoadjuvant treatment for pancreatic cancer: a comparison between neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy. Ann Gastroenterol Surg 9:1312\u20131321. https:\/\/doi.org\/10.1002\/ags3.70047","journal-title":"Ann Gastroenterol Surg"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03071-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03071-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03071-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T16:35:43Z","timestamp":1784997343000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03071-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3071"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03071-6","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"29 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki. Ethical approval was obtained from the Ethical Review Committee of Osaka International Cancer Institute (24052).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent was waived by using the opt-out method on our hospital\u2019s website.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K.Ikezawa reports honoraria from Taiho Pharmaceutical, AstraZeneca, MSD, Nihon Servier, Chugai Pharmaceutical, Guardant Health Japan, Eisai, TAKATA Pharmaceutical, and Myriad Genetics. R.T. reports honoraria from AstraZeneca, Merck, and Novartis. M.S. reports honoraria from Novartis, AstraZeneca, Nihon Servier, Teijin Pharma, and MSD. H.T. reports honoraria from Taiho Pharmaceutical, Novartis, Viatris, AstraZeneca, Daiichi Sankyo, Bristol Myers Squibb, ONO Pharmaceutical, Merck, Nihon Servier, and Terumo Corporation. S.K. reports honoraria from AstraZeneca, Covidien, Ethicon, Intuitive, MSD, Novartis, and Taiho Pharmaceutical. K.O. reports honoraria from Chugai Pharmaceutical, Eisai, AstraZeneca, and Incyte","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}